TY - JOUR
T1 - Antioxidant and acetylcholinesterase inhibition activity of aliphatic and aromatic edaravone derivatives
AU - Barajas-Carrillo, Victor Wagner
AU - Estolano-Cobián, Arturo
AU - Díaz-Rubio, Laura
AU - Ayllón-Gutiérrez, Rocío Rosario
AU - Salazar-Aranda, Ricardo
AU - Díaz-Molina, Raúl
AU - García-González, Víctor
AU - Almanza-Reyes, Horacio
AU - Rivero, Ignacio A.
AU - Marrero, Joaquín G.
AU - Córdova-Guerrero, Iván
N1 - Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2021/3
Y1 - 2021/3
N2 - As Alzheimer disease (AD) is a multifactorial condition, it should be tackled with drugs targeting multiple key pathways. A series of aliphatic (2–8) and aromatic (9–15) edaravone derivatives were synthesized, characterized, and evaluated as antioxidant agents using 1,1-diphenyl-2-picrylhydrazyl (DPPH) and 2-2’-azino-bis-(3-ethylbenzothiazoline-6-sulfonate) (ABTS·+) assays, as well as acetylcholinesterase (AChE) inhibitors. In both antioxidant assays, even though the starting compound edaravone was more active, the best derivative was 5 with 50% effective concentration (EC50) of 0.0301 and 0.8106 mM respectively, followed by 3 (EC50 of 0.1920 mM and 3.5311 mM). In the AChE inhibition assay, the derivatives were not as active as the positive control galantamine, but a general better activity was shown from the aromatic compounds. The best results were for 10, with 41.9% of inhibition (concentration of 150 μg/mL), and 9 with 31.6%. Docking analysis of compound 10 showed hydrogen bonds with residues Ser200 and His440 in the AChE catalytic gorge. All synthesized derivatives 2–15 presented drug-like properties and are capable of crossing the blood–brain barrier and not be pumped out of it. These results indicate edaravone derivatives can function as scaffolds for AD drugs, though further derivatizations should be conducted to improve their antioxidant and AChE inhibition profiles. [Figure not available: see fulltext.]
AB - As Alzheimer disease (AD) is a multifactorial condition, it should be tackled with drugs targeting multiple key pathways. A series of aliphatic (2–8) and aromatic (9–15) edaravone derivatives were synthesized, characterized, and evaluated as antioxidant agents using 1,1-diphenyl-2-picrylhydrazyl (DPPH) and 2-2’-azino-bis-(3-ethylbenzothiazoline-6-sulfonate) (ABTS·+) assays, as well as acetylcholinesterase (AChE) inhibitors. In both antioxidant assays, even though the starting compound edaravone was more active, the best derivative was 5 with 50% effective concentration (EC50) of 0.0301 and 0.8106 mM respectively, followed by 3 (EC50 of 0.1920 mM and 3.5311 mM). In the AChE inhibition assay, the derivatives were not as active as the positive control galantamine, but a general better activity was shown from the aromatic compounds. The best results were for 10, with 41.9% of inhibition (concentration of 150 μg/mL), and 9 with 31.6%. Docking analysis of compound 10 showed hydrogen bonds with residues Ser200 and His440 in the AChE catalytic gorge. All synthesized derivatives 2–15 presented drug-like properties and are capable of crossing the blood–brain barrier and not be pumped out of it. These results indicate edaravone derivatives can function as scaffolds for AD drugs, though further derivatizations should be conducted to improve their antioxidant and AChE inhibition profiles. [Figure not available: see fulltext.]
KW - ADME calculation
KW - Acetylcholinesterase inhibition
KW - Antioxidant
KW - Docking
KW - Edaravone
UR - http://www.scopus.com/inward/record.url?scp=85096405359&partnerID=8YFLogxK
U2 - 10.1007/s00044-020-02667-5
DO - 10.1007/s00044-020-02667-5
M3 - Artículo
AN - SCOPUS:85096405359
SN - 1054-2523
VL - 30
SP - 610
EP - 623
JO - Medicinal Chemistry Research
JF - Medicinal Chemistry Research
IS - 3
ER -